New external innovation investment fund helps GSK tap in to Canadian innovation
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has today launched its $50 million Canada Life Sciences Innovation Fund that will invest in early stage breakthrough research. The firm says the fund, the first of its kind with a "dedicated mandate for Canada," will extend the GSK's collaborative focus.